Chest Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pearson, F. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pearson, F. G.
(Chest. 1999;116:500S-503S.)
© 1999 American College of Chest Physicians

Non-small Cell Lung Cancer*

Role of Surgery for Stages I-III

F. Griffith Pearson, MD

* From Toronto General Hospital, Toronto, Ontario, Canada.

Correspondence to: F. Griffith Pearson, MD, Toronto General Hospital, Eaton North 10–233, 200 Elizabeth St, Toronto, Ontario, Canada M5G-2C4; e-mail: pearson{at}user.rose.com

Survival following surgical resection of non-small cell lung cancer (NSCLC) has improved since the 1960s, although the 5-year survival rate remains low. This article provides an overview of the role of surgery for NSCLC stages I-III, with a focus on optimizing long-term survival in those patients with resectable disease. Topics explored include diagnosis and staging, indications for resection, types of resection, and indications for adjuvant therapy. A review of the literature indicates a clear survival advantage for complete resection, and is suggestive of an advantage for mediastinal lymph node dissection (vs lymph node sampling) and neoadjuvant therapy (vs adjuvant therapy).




This article has been cited by other articles:


Home page
ChestHome page
M. Licker, A. Spiliopoulos, J.-G. Frey, J. Robert, L. Hohn, M. de Perrot, and J.-M. Tschopp
Risk Factors for Early Mortality and Major Complications Following Pneumonectomy for Non-small Cell Carcinoma of the Lung*
Chest, June 1, 2002; 121(6): 1890 - 1897.
[Abstract] [Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
S. Elia, S. Griffo, M. Gentile, R. Costabile, and G. Ferrante
Surgical treatment of lung cancer invading chest wall: a retrospective analysis of 110 patients
Eur. J. Cardiothorac. Surg., August 1, 2001; 20(2): 356 - 360.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the American College of Chest Physicians.